Currently available first-line anti-AD drugs are acetyl- (AChE) and/or butyrylcholinesterase (BuChE) inhibitors that enhance disrupted cholinergic neurotransmission, temporarily relieving cognitive symptoms and slowing the disease progression [5]. This evidence concerns the gene BCHE and Alzheimer disease.